Katherine Huppler Hullsiek, Ph.D.

Research Associate
Division of Biostatistics
School of Public Health

2221 University Ave SE, Suite 200
Minneapolis, Minnesota 55414

Phone: (612) 626-0314
Fax: (612) 626-8892
email: hulls003@umn.edu

I am a co-principal investigator for the Data Analysis Center (DAC) for the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense tri-service program for the advancement of military medicine. I am also a biostatistician at the Statistical and Data Management Center (SDMC) of the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT).

Papers

• Chun HM, Fieberg AM, Huppler Hullsiek K, Lifson AF, Crum-Cianflone NF, Weintrob AC, Ganesan A, Barthel RV, Bradley WP, Agan BK, Landrum ML. The epidemiology of hepatitis B virus infection in a U.S. cohort of HIV-infected individuals during the last 20 years. Accepted for publication September 2009, Clinical Infectious Disases.

• Baker J, Ayenew W, Quick H, Huppler Hullsiek K, Tracy R, Henry K, Duprez D, Neaton JD. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. Accepted for publication August 2009, Journal of Infectious Diseases.

• Crum-Cianflone NF, Huppler Hullsiek K, Marconi VC, Ganesan A, Weintrob A, Barthel RV, Agan BK. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. Accepted for publication August 2009, AIDS.

• Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel V, O'Connell RJ, Fieberg A, Chun HM, Marconi VC, Dolan MJ, Agan BK. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. Accepted for publication April 2009, AIDS.

• Baker JV, Duprez D, Rapkin J, Huppler Hullsiek K, Quick H, Grimm R, Neaton JD, Henry K. Untreated HIV infection and large and small artery elasticity. JAIDS, 2009; 52(1):25-31.

• Landrum ML, , Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, Peel S, Agan BK. Hepatitis B vaccine response in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine, 2009; 27:4731-4738.

• Crum-Cianflone N, Huppler Hullsiek K, Satter E, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan B. Cutaneous malignancies among HIV-infected persons. Archives of Internal Medicine, 2009; 169(12):1130-1138.

• Crum-Cianflone N, Huppler Hullsiek K, Marconi V, Weintrob A, Ganesan A, Barthel V, Fraser S, Poehlman Roediger M, Agan B, Wegner s. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. JAIDS, 2009; 51(3):305-309.

• Simen B, Simons JF, Huppler Hullsiek K, Novak RM, MacArthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ. Low abundance drug resistant variants in chronically HIV-infected antiretroviral naive patients significnatly impact treatment outcome. Journal of Infectious Diseases, 2009;199:693-701.

• Crum-Cianflone NC, Huppler Hullsiek K, Marconi V, Weintrob A, Ganesan A, Barthel V, Fraser S, Agan B, Wegner S. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20 year cohort study. AIDS, 2009; 23:41-50 .

• van den Berg-Wolf M, Huppler Hullsiek K, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, MacArthur RD. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1 infected persons. HIV Clinical Trials, 2008; 9:324-336.

• Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Huppler Hullsiek K, Stephan C, Lundgren J. Viral resuppression and detection of drug resistance following interruption of a suppressive NNRTI-based regimen. AIDS, 2008; 22(17):2279-2289.

• Mannheimer SB, Wold N, Gardner EM, Telzak EE, Huppler Hullsiek K, Chesney M, Wu AW, MacArthur RD, Matts J, Friedland G. Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected indivuals. Clinical Infectious Diseases, 2008; 46(6):941-5.

• Mannheimer S, Thackeray L, Huppler Hullsiek K, Chesney M, Gardner E, Wu A, Telzak E, Lawrence J, Baxter J, Friedland G. A randomized comparison of two instruments for measuring self-reported adherence. AIDS Care, 2008; 20(2):161-169.

• Gardner EM, Sharma S, Peng G, Huppler Hullsiek K, Burman WJ, MacArthur RD, Chesney M, Telzak EE, Friedland G, Mannheimer SB. Differential adherence to components of combination antiretroviral therapy is associated with virologic failure and antiretroviral resistance. AIDS, 2008; 22:75-82.

• Kozal MJ, Huppler Hullsiek K, MacArthur RD, van den Berg-Wolf M, Peng G, Xiang Y, Baxter JD, Uy J. The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clinical Trials, 2007; 8:357-370.

• MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Huppler Hullsiek K, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet, 2006; 368:2125-2135.

• Lawrence J, Huppler Hullsiek K, Thackeray L, Abrams D, Crane L, Mayers D, Jones M, Saldanha J, Schmetter B, Baxter J. Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: Final results of the CPCRA 064 Study. Journal of Acquired Immune Deficiency Syndromes, 2006; 43:169-178.

• Kozal M, Huppler Hullsiek K, Leduc R, Novak R, MacArthur R, Lawrence J, Baxter J. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients enrolling in clinical trials. Antiviral Therapy, 2006; 11:457-463.

• Novak R, Chen L, MacArthur R, Baxter J, Huppler Hullsiek K, Peng G, Xiang Y, Henley C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M, and the Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team. Prevalence of antiretroviral drug resistance mutations in chronically human immunodeficiency virus-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clinical Infectious Diseases, 2005; 40:468-474.

• Lawrence J, Mayers D, Huppler Hullsiek K, Collins G, Abrams D, Reisler R, Crane L, Schmetter B, Dionne T, Saldanha J, Jones M, Baxter J. Structured treatment interruption in patients with multi-drug resistant Human immunodeficiency Virus. New England Journal of Medicine , 2003; 349:837-846.

• Tedaldi E, Huppler Hullsiek K, Malvestutto C, Arduino R, Fisher E, Gaglio P, Jenny-Avital E, McGowan J, Perez G. Prevalence and characteristics of HCV coinfection in an HIV clinical trials group. Clinical Infectious Diseases. 2003; 36:1313-1317.

• Han C., Pulling CC, Telke SE, Huppler Hullsiek K. Assessing the utility of five domains in the SF-12 Health Status questionnaire in an AIDS clinical trial. AIDS , 2002; 16:431-439.

• Huppler Hullsiek K,, Louis TA. Propensity score modeling strategies for the causal analysis of observational data. Biostatistics. 2002; 4:179-193.

Oral Presentations

• Crum-Cianflone NF, Huppler Hullsiek K, Marconi V, Weintrob A, Ganesan A, Barthel V, Fraser S, Agan B. Anal cancers among HIV-infected persons. Accepted for 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa; 19-22 July 2009.

• Telzak E, Huppler Hullsiek K, Mannheimer S, Peng G, Sharma S, Gardner E, MacArthur R, Chesney M, Friedland G. Adherence and its impact on virologic failure and resistance: Results of the FIRST study. Infectious Disease Society of America 45th Annual Meeting. San Diego, CA; October 3-7 2007.

• Simen BB, Huppler Hullsiek K, Novak RM, MacArthur RD, Baxter JD, Huang C, Lebeski C, Turenchalk GS, Braverman MS, Desany B, Simons JF, Rothberg JM, Egholm M, Kozal MJ. Prevalence of low abundant drug resistant variants by ultra-deep sequencing in chronically HIV-infected antiretroviral naive patients and the impact on virologic outcomes. XVI International HIV Drug Resistance Workshop. Barbados, West Indies; June 2007. Antivir Ther 2007; 12(S149):Abstract number 134.

• MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Kozal MJ, van den Berg-Wolf M, Henely C, Huppler Hullsiek K, Schmetter B, Dehlinger M. Long-term clinical and immunologic outcomes are similar in HIV-infected persons randomized to a NNRTI vs PI vs NNRTI+PI-based antiretroviral regimens as initial therapy. XVI International AIDS Conference. Toronto, Canada, August 13-18, 2006.

• Mannheimer S, Thackeray L, Huppler Hullsiek K, Chesney M, Gardner E, Wu A, Telzak E, Lawrence J, Baxter J, Friedland G. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. 2006 NIMH/IAPAC International Conference on HIV Treatment Adherence. Jersey City, New Jersey, March 8-10, 2006.

• Huppler Hullsiek K. Stopping enrollment to a trial based on safety guidelines: lessons learned in CPCRA 064. 25th Annual meeting of the Society for Clinical Trials. New Orleans, Louisiana, May 23-26, 2004.

• Lawrence J, Huppler Hullsiek K, Mayers D, Abrams D, Reisler R, Crane L, Schmetter B, Dionne T, Saldanha J, Jones M, Baxter J. Failure of structured treatment interruption to confer benefit in the setting of treatment failure: CPCRA 064 results by baseline CD4 count and phenotypic sensitivity score subgroups. Second International AIDS Society Conference on Pathogenesis and Treatment. Paris, France 2003.

• Lawrence J, Mayers D, Huppler Hullsiek K, Collins G, Abrams D, Reisler R, Crane L, Schmetter B, Dionne T, Saldanha J, Jones M, Baxter J. CPCRA 064: A randomized trial examining structured treatment interruption for patients failing therapy with multi-drug resistant HIV. 10th Conference on Retroviruses and Opportunistic Infections (abstract #67). Boston MA, Feb 10-14, 2003.

• Huppler Hullsiek K, Louis TA. Determining propensity score subclass boundaries for the causal analysis of observational data. International Biometric Society Eastern North American Region 2000 Spring Meeting. Chicago, IL, March 21, 2000.

Scientific Posters

• Crum-Cianflone NF, Huppler Hullsiek K, Marconi V, Weintrob A, Ganesan A, Barthel V, Fraser S, Agan B. What CD4 cell count levels are associated with a reduced risk of cancer? Accepted for 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa; 19-22 July 2009.

• Crum-Cianflone NF, Huppler Hullsiek K, Marconi V, Weintrob A, Ganesan A, Barthel V, Fraser S, Agan B. The impact of NNRTIs compared to PIs on cancer. Accepted for 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa; 19-22 July 2009.

• Landrum M, Huppler Hullsiek K, Ganesan A, Weintrob A, Crum-Cianflone N, Barthel V, Agan B. Hepatitis B immunization prior to HIV diagnosis and risk of subsequent Hepatitis B infection. 16th Conferene on Retroviruses and Opportunistic Infections . Montreal, Canada; February 8-11, 2009.

• Landrum M, Huppler Hullsiek K, Ganesan A, Weintrob A, Crum-Cianflone N, Barthel V, Peel S, Agan B. Highly Active Antiretroviral Therapy improves response to Hepatitis B vaccine in HIV-infected individuals regardless of CD4 cell count. Infectious Disease Society of America 46th Annual Meeting. Washington, DC: October 25-28, 2008.

• Crum-Cianflone N, Huppler Hullsiek K, Ganesan A, Weintrob A, Marconi V, Fraser S, Roediger M, Barthel V, Agan B, Wegner S. The impact of nelfinavir on cancer development among HIV-infected persons. XVII International AIDS Conference. Mexico City, Mexico, 3-8 August 2008.

• MacArthur RD, Huppler Hullsiek K, Peng G, van den Berg-Wolf M, Crane LR, Novak RM, Chen L, Kozal MJ. Failing therapy with efavirenz results in significantly fewer mutations limiting to etravirine than failing therapy with nevirapine: on-treatment anlayses from the CPCRA FIRST study. XVII International Drug Resistance Workshop. Sitges Spain, 10-13 June 2008.

• Huppler Hullsiek K , Peng G, Simen B, Simons J, Egholm M, Novak R, MacArthur R, Kozal M. Virologic success of different strategies for initial ART antiretroviral therapy regimens is predicted by the type and detection level of minor drug-resistant variants detected by Ultra Deep Sequencing: the CPCRA FIRST stduy. 15th Conferene on Retroviruses and Opportunistic Infections . Boston, MA, February 3-6, 2008.

• Landrum M, Huppler Hullsiek K, Ganesan A, Weintrob A, Crum-Cianflone N, Barthel V, Chun H, Agan B. The clinical efficacy of Hepatitis B vaccine in HIV-infected individuals. Infectious Disease Society of America 45th Annual Meeting. San Diego, CA: October 3-7 2007.

• MacArthur RD, Peng G, Huppler Hullsiek K, Novak RM, van den Berg-Wolf M, Uy J, Shweta S, Chen L, Xiang Y, Kozal MJ. Long-term virologic, immunologic, and clinical outcomes are similar in HIV-infected persons taking indinavir versus nelfinavir versus ritonavir-boosted protease inhibitor-based antiretroviral regimens as initial therapy. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia; July 2007.

• Gardner EM, Sharma S, Peng G, Huppler Hullsiek K, Burman WJ, MacArthur RD, Chesney M, Telzak EE, Friedland G, Mannheimer SB. Selective nonadherence to components of combination antiretroviral therapy is associated with virologic failure and antiretroviral resistance. 2007 International conference on HIV Treatment Adherence. Jersey City, New Jersey; March 2007.

• van den Berg-Wolf M, Peng G, Xiang Y, Huppler Hullsiek K, Chen L, MacArthur R, Novak M, Kozal M, Schmetter B, Henely C, Dehlinger M. Efficacy and safety of nevirapine versus efavirenz in antiretroviral regimens in HIV infected antiretroviral naove persons. XVI International AIDS Conference. Toronto, Canada, August 13-18, 2006.

• Kozal MJ, Huppler Hullsiek K, MacArthur RD, Peng G, Xiang Y, Baxter JD, van den Berg Wolf M, Uy J, Telzak EE, Novak RM. Initial virologic failure with HIV drug resistance and impact of resistance on disease progression and death for patients beginning PI, NNRTI, or PI+NNRTI based strategies: the FIRST study. XV International HIV Drug Resistance Workshop. Sitges, Spain; June 13-17, 2006.

• Lawrence J, Huppler Hullsiek K, Coakley E, Bates M, Weidler J, Lie Y, Pesano R, Thackeray L, Baxter J. Antiretroviral phenotypic susceptibility score as a predictor of treatment response in persons with multidrug-resistant HIV-1. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO. Feb 5-8, 2006.

• Kozal MJ, Huppler Hullsiek K, Leduc R, Novak RM, MacArthur RD, Lawrence J, Baxter J. Prevalence and impact of protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients enrolling in clinical trials. XIV International HIV Drug Resistance Workshop. Quebec City, Quebec, Canada; June 7-11, 2005.

• Lawrence J, Huppler Hullsiek K, Thackeray L, Abrams D, Mayers D, Crane L, Jones M, Saldanha J, Scmetter B, Dionne T, Pettinelli C, Baxter J for the 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS. Final Results of CPCRA 064: A randomized trial examining structured treatment interruption for patients failing therapy with multi-drug resistant HIV. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, Feb 22-25, 2005.

• Novak RM, Chen L, MacArthur RD, Baxter J, Huppler Hullsiek K , Peng G, Xiang Y, Henley C, Schmetter B, Uy J, van den Berg-Wold, Kozal M, and the CPCRA 058 Study Team. Prevalence of resistance mutations in a cohort of treatment-naive people with chronic HIV infection: CPCRA 058. XV International AIDS Conference. Thailand, July 2004.

• Lawrence J, Huppler Hullsiek K, Abrams D, Schmetter B, Baxter J, and the CPCRA 064 Study Team. Patterns of CD4 and HIV-1 RNA change during structured treatment interruption in patients with multidrug-resistant HIV. XIII International HIV Resistance Workshop. Tenerife Sur, Canary Islands. Spain, June 8-14, 2004.

• Lawrence J, Huppler Hullsiek K, Abrams D, Baxter J. Changes in HIV resistance patterns during structured treatment interruption: CPCRA 064. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, Feb 8-11, 2004.

• Lawrence J, Huppler Hullsiek K, Mayers D, Abrams D, Baxter J. Baseline resistance and predictors of virologic response in the CPCRA 064 study: A randomized trail of structured treatment interruptions for patients with multi-drug resistant virus. XII International HIV Drug Resistance Workshop. Cabo del Sol, Los Cabos Mexico, June 10-14, 2003.

• Lawrence J, Mayers D, Huppler Hullsiek K, Schmetter B, Abrams D, Baxter J for the CPCRA 064 Study Team. Simultaneous genotypic and phenotypic HIV resistance testing and influence on treatment selection in the CPCRA 064 (MDR) study. Abstract #B11177XIV, 6th International Workshop on HIV Drug Resistance and Treatment Strategies. Seville, Spain, July 2-5 2002.

• Tedaldi EM, Huppler Hullsiek K, Malvestutto CD, Arduino RC, Fisher EJ, Gaglio PJ, Jenny-Avital ER, McGowan JP, Perez G. Prevalence and characteristics of HCV coinfection in an HIV clinical trials group. Abstract #545, 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, July 2001.

Other Links

Mandatory statement:

"The views and opinions expressed in this page are strictly those of the page author.
The contents of this page have not been approved by the University of Minnesota."